Form 4: Essa Pharma COO Sells Shares Under 10b5-1 Trading Plan

Peter Virsik, Chief Operating Officer of Essa Pharma Inc., sold 2,082 common shares at a weighted average price of $6.03 per share on September 3, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Peter Virsik, the Chief Operating Officer of Essa Pharma Inc., reported a transaction involving the sale of company shares.
• On September 3, 2024, Virsik sold 2,082 common shares.
• The sale was executed under a Rule 10b5-1 trading plan established on August 31, 2023.
• The weighted average price for the shares sold was $6.03.
• Following the transaction, Virsik directly owns 9,164 common shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily reflect a change in the insider's view of the company.

Industry Context

Sales by company insiders are a common occurrence, and the use of 10b5-1 trading plans allows insiders to sell shares over a period of time while avoiding concerns about insider trading. Investors often monitor insider transactions for signals about a company's prospects, but sales under a 10b5-1 plan are generally viewed as less informative than discretionary sales.

Stakeholder Impact

• The sale of shares by a company officer could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates